PROFILPELAJAR.COM

KLK9
Identifiers
Aliases	KLK9, KLK-L3, KLKL3, kallikrein related peptidase 9
External IDs	OMIM: 605504; MGI: 1921082; HomoloGene: 40832; GeneCards: KLK9; OMA:KLK9 - orthologs
Gene location (Human)
Chr.	Chromosome 19 (human)
End	51,009,634 bp
Gene location (Mouse)
Chr.	Chromosome 7 (mouse)
End	43,446,181 bp
RNA expression pattern
	Top expressed in
	skin of leg; ; skin of abdomen; ; mucosa of esophagus; ; tonsil; ; vagina; ; right uterine tube; ; ectocervix; ; minor salivary glands; ; prefrontal cortex; ; endometrium;
	Top expressed in
	esophagus; ; lip; ; zone of skin; ; embryo; ; genital tubercle; ; stomach; ; tail of embryo; ; urinary bladder; ; placenta; ; thymus;
	More reference expression data
	n/a
Gene ontology
Molecular function	peptidase activity; serine-type peptidase activity; hydrolase activity; serine-type endopeptidase activity;
Cellular component	extracellular region; secretory granule;
Biological process	proteolysis;
	Sources:Amigo / QuickGO
Orthologs
	284366
	101533
	ENSG00000213022
	ENSMUSG00000047884
	Q9UKQ9
	Q32M27
	NM_012315
	NM_028660
	NP_036447
	NP_082936
	Wikidata
View/Edit Human	View/Edit Mouse

Kallikrein-related peptidase 9 also known as KLK9 is an enzyme which in humans is encoded by the KLK9 gene.^[5]

Function

KLK9 belongs to the kallikrein subgroup of serine proteases, which have diverse physiologic functions in many tissues.^[6]^[7]^[8] KLK9 is primarily expressed in thymus, testis, spinal cord, cerebellum, trachea, mammary gland, prostate, brain, salivary gland, ovary, and skin.^[5]

Clinical significance

KLK9 is under steroid hormone regulation in ovarian and breast cancer cell lines and is a potential prognostic marker for early-stage ovarian^[9] and breast cancer patients.^[10]

References

^ ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000213022 – Ensembl, May 2017
^ ^a ^b ^c GRCm38: Ensembl release 89: ENSMUSG00000047884 – Ensembl, May 2017
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ ^a ^b Yousef GM, Diamandis EP (April 2000). "The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9)". Genomics. 65 (2): 184–94. CiteSeerX 10.1.1.326.8491. doi:10.1006/geno.2000.6159. PMID 10783266.
^ "Entrez Gene: KLK9".
^ Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, Fritz H, Lilja H, Malm J, Maltais LJ, Olsson AY, Petraki C, Scorilas A, Sotiropoulou G, Stenman UH, Stephan C, Talieri M, Yousef GM (June 2006). "A comprehensive nomenclature for serine proteases with homology to tissue kallikreins" (PDF). Biological Chemistry. 387 (6): 637–41. doi:10.1515/BC.2006.082. PMID 16800724. S2CID 436200.
^ Diamandis EP, Deperthes D, Lundwall Å (June 2006). "Proceedings of the 1st International Symposium on Kallikreins, Lausanne, Switzerland, September 1-3, 2005". Biological Chemistry. 387 (6): 635–824. doi:10.1515/BC.2006.081. PMID 16800723. S2CID 83910246.
^ Yousef GM, Kyriakopoulou LG, Scorilas A, Fracchioli S, Ghiringhello B, Zarghooni M, Chang A, Diamandis M, Giardina G, Hartwick WJ, Richiardi G, Massobrio M, Diamandis EP, Katsaros D (November 2001). "Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker". Cancer Research. 61 (21): 7811–8. PMID 11691797.
^ Yousef GM, Scorilas A, Nakamura T, Ellatif MA, Ponzone R, Biglia N, Maggiorotto F, Roagna R, Sismondi P, Diamandis EP (March 2003). "The prognostic value of the human kallikrein gene 9 (KLK9) in breast cancer". Breast Cancer Research and Treatment. 78 (2): 149–58. doi:10.1023/A:1022931403825. PMID 12725415. S2CID 6515644.